Filtered By:
Management: Food and Drug Administration (FDA)
Vaccination: Cancer Vaccines
This page shows you your search results in order of date.
Order by Relevance | Date
Total 128 results found since Jan 2013.
United States' regulatory approved pharmacotherapies for nuclear reactor explosions and anthrax-associated bioterrorism
Expert Opin Drug Saf. 2023 Aug 18:1-6. doi: 10.1080/14740338.2023.2245748. Online ahead of print.ABSTRACTINTRODUCTION: Nuclear reactor incidents and bioterrorism outbreaks are concerning public health disasters. Little is known about US Food and Drug Administration (FDA)-approved agents that can mitigate consequences of these events. We review FDA data supporting regulatory approvals of these agents.AREAS COVERED: We reviewed pharmaceutical products approved to treat Hematopoietic Acute Radiation Syndrome (H-ARS) and to treat or prevent pulmonary infections following Bacillus anthracis (anthrax) exposure. Four drugs were a...
Source: Expert Opinion on Drug Safety - August 18, 2023 Category: Drugs & Pharmacology Authors: Charles L Bennett Peter Georgantopoulos Robert Peter Gale Kevin Knopf William J Hrushesky Chadi Nabhan James O Armitage Source Type: research
Predictors of SARS-CoV-2 Omicron breakthrough infection after receipt of AZD7442 (tixagevimab-cilgavimab) for pre-exposure prophylaxis among hematologic malignancy patients
Haematologica. 2023 Jun 22. doi: 10.3324/haematol.2023.283015. Online ahead of print.ABSTRACTAZD7442 (tixagevimab-cilgavimab) is a combination of two human monoclonal antibodies for preexposure prophylaxis of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among highrisk patients who do not mount a reliable vaccine response. Foremost among these are hematologic malignancy patients with limited clinical trial or real-world experience to assess the effectiveness of this combination treatment since the emergence of Omicron and its subvariants. We performed a retrospective study of 892 highrisk hematolog...
Source: Haematologica - June 22, 2023 Category: Hematology Authors: Justin C Laracy Judy Yan Samantha N Steiger Carrie A Tan Nina Cohen Elizabeth V Robilotti Jerome Fender Sara Cohen Neha Korde Melissa Lee-Teh Ariela Noy Joseph H Oved Lindsey E Roeker Gunjan Shah N Esther Babady Mini Kamboj Susan K Seo Source Type: research
Research Progress of Immunotherapy for Gastric Cancer
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221150555. doi: 10.1177/15330338221150555.ABSTRACTGastric cancer (GC) is one of the most common gastrointestinal tract cancers worldwide, which has high incidence and mortality rates and poor prognosis. Although multidisciplinary comprehensive therapies consisting of surgery, chemotherapy, radiotherapy, and targeted therapy have made great progress in GC treatment, a satisfactory curative effect still cannot be achieved in many circumstances, and the 5-year survival of patients with GC remains to be very low. In China, about 75% of patients with GC are diagnosed in the adva...
Source: Technology in Cancer Research and Treatment - April 12, 2023 Category: Cancer & Oncology Authors: Zhipeng Zhang Ningning Liu Mingyu Sun Source Type: research
Acceptability and readiness to promote human papillomavirus vaccination at ages 9-10 years: A pilot study among rural North Carolina clinics
Res Sq. 2023 Jan 30:rs.3.rs-2326137. doi: 10.21203/rs.3.rs-2326137/v1. Preprint.ABSTRACTWhile 9-valent human papillomavirus vaccination (HPV-9) is approved by the U.S. Food and Drug Administration for use in adolescents as young as age 9, providers typically recommend it at ages 11-12 per Centers for Disease Control and Prevention recommendations. Studies suggest that recommending HPV-9 at 9 or 10 years of age could increase up-to-date vaccination by age 13, which could benefit rural populations with reduced access to primary health care and lower HPV-9 coverage than urban areas. This pilot study aimed to assess the feasib...
Source: Cancer Control - February 13, 2023 Category: Cancer & Oncology Authors: Nadja Vielot Robyn M Lane Kaitlyn Loefstedt Jennifer Cunningham Jason Everson Eli Tiller Sallie Patel Jennifer Smith Source Type: research
Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge one year later
Sci Transl Med. 2022 Dec 1:eadd6383. doi: 10.1126/scitranslmed.add6383. Online ahead of print.ABSTRACTThe U.S. Food and Drug Administration only gave emergency-use-authorization of the BNT162b2 and the mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet, questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3 M-052, a synthe...
Source: Cancer Control - December 1, 2022 Category: Cancer & Oncology Authors: Emma C Milligan Katherine Olstad Caitlin A Williams Michael Mallory Patricio Cano Kaitlyn A Cross Jennifer E Munt Carolina Garrido Lisa Lindesmith Jennifer Watanabe Jodie L Usachenko Lincoln Hopkins Ramya Immareddy Yashavanth Shaan Lakshmanappa Sonny R El Source Type: research
Weekly Overseas Health IT Links – 15th October, 2022.
This article uses the one that divides providers into groups depending on the life cycle stage the clinic is at the given moment. According to this classification, medical providers fall into three groups:BeginnersGrowing clinicsWell-established providersHealth care providers are business entities, so their life cycle, like that of any business, consists of the early stage or launch, growth and maturity. At each stage, providers have different priorities and goals, and the choice of medical software solutions should be made accordingly.Medical software for beginnersThe launch phase can be tough. At this stage, the profits ...
Source: Australian Health Information Technology - October 15, 2022 Category: Information Technology Authors: Dr David G More MB PhD Source Type: blogs
